The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Open accessAbstract
The MYC proto-oncogenes encode a family of transcription factors that are among the most commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or upregulation of MYC-related pathways by alternate mechanisms occur in the vast majority of cancers. MYC proteins are master regulators of cellular programmes. Thus, cancers with MYC activation elicit many of the hallmarks of cancer required for autonomous neoplastic growth. In preclinical models, MYC inactivation can result in sustained tumour regression, a phenomenon that has been attributed to oncogene addiction. Many therapeutic agents that directly target MYC are under development; however, to date, their clinical efficacy remains to be demonstrated. In the past few years, studies have demonstrated that MYC signalling can enable tumour cells to dysregulate their microenvironment and evade the host immune response. Herein, we discuss how MYC pathways not only dictate cancer cell pathophysiology but also suppress the host immune response against that cancer. We also propose that therapies targeting the MYC pathway will be key to reversing cancerous growth and restoring antitumour immune responses in patients with MYC -driven cancers. The MYC proto-oncogenes are among the most commonly activated proteins in human cancer, yet the clinical efficacy of MYC-targeted agents remains to be demonstrated. The authors of this Review describe how activation of the MYC pathway affects cancer cells as well as the tumour microenvironment and propose strategies for the therapeutic targeting of MYC -driven cancers. The MYC oncogene is activated in the vast majority of cancers by genetic, epigenetic or post-translational mechanisms. In preclinical models, inactivation of MYC can result in sustained tumour regression owing to oncogene addiction. MYC activation drives cancer progression through mechanisms involving either the cell-intrinsic acquisition of hallmarks of cancer or dysregulation of the tumour microenvironment and host immune responses. MYC leads to cancer initiation and maintenance by regulating the host immune system through mechanisms involving immune checkpoints, specific receptors and secreted cytokines. Currently, no direct inhibitors of MYC are approved; however, many therapeutic agents targeting MYC are under development. We propose that therapies targeting the MYC pathway will be key to reversing cancerous growth and restoring antitumour immune responses in patients with MYC-driven cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
c-Myc-regulated microRNAs modulate E2F1 expression
O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005) · Nature · doi:10.1038/nature03677 · Cited by 2,347
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Self-citationMultiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
Grandori, C., Cowley, S. M., James, L. P., & Eisenman, R. N. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.653 · Cited by 1,333
Widespread microRNA repression by Myc contributes to tumorigenesis
Chang, T.-C., Yu, D., Lee, Y.-S., Wentzel, E. A., Arking, D. E., West, K. M., Dang, C. V., Thomas-Tikhonenko, A., & Mendell, J. T. (2008) · Nature Genetics · doi:10.1038/ng.2007.30 · Cited by 1,325
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.009 · Cited by 1,095
Self-citationc-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Direct activation of TERT transcription by c-MYC
Wu, K.-J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., & Dalla-Favera, R. (1999) · Nature Genetics · doi:10.1038/6010 · Cited by 893
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Self-citationDeregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 879
c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
Self-citationc-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma
Weng, A. P., Millholland, J. M., Yashiro-Ohtani, Y., Arcangeli, M. L., Lau, A., Wai, C., del Bianco, C., Rodriguez, C. G., Sai, H., Tobias, J., et al. (2006) · Genes & Development · doi:10.1101/gad.1450406 · Cited by 870
Self-citationTargeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 855
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
Turner, K. M., Deshpande, V., Beyter, D., Koga, T., Rusert, J., Lee, C., Li, B., Arden, K., Ren, B., Nathanson, D. A., et al. (2017) · Nature · doi:10.1038/nature21356 · Cited by 847
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
Self-citationTeitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Metabolic coordination of T cell quiescence and activation
Chapman, N. M., Boothby, M. R., & Chi, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0203-y · Cited by 751
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747
Role for c-myc in Activation-Induced Apoptotic Cell Death in T Cell Hybridomas
Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., & Green, D. R. (1992) · Science · doi:10.1126/science.1378649 · Cited by 695
Circular ecDNA promotes accessible chromatin and high oncogene expression
Wu, S., Turner, K. M., Nguyen, N., Raviram, R., Erb, M., Santini, J., Luebeck, J., Rajkumar, U., Diao, Y., Li, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1763-5 · Cited by 667
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Non-transcriptional control of DNA replication by c-Myc
Dominguez-Sola, D., Ying, C. Y., Grandori, C., Ruggiero, L., Chen, B., Li, M., Galloway, D. A., Gu, W., Gautier, J., & Dalla-Favera, R. (2007) · Nature · doi:10.1038/nature05953 · Cited by 651
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
Self-citationCDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Drosophila Myc Regulates Organ Size by Inducing Cell Competition
de la Cova, C., Abril, M., Bellosta, P., Gallant, P., & Johnston, L. A. (2004) · Cell · doi:10.1016/s0092-8674(04)00214-4 · Cited by 609
MYC, Metabolism, Cell Growth, and Tumorigenesis
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 602
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression
Baudino, T. A., McKay, C., Pendeville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., & Cleveland, J. L. (2002) · Genes & Development · doi:10.1101/gad.1024602 · Cited by 525
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
FBXW7: a critical tumor suppressor of human cancers
Yeh, C.-H., Bellon, M., & Nicot, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0857-2 · Cited by 515
Soucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B., & Evan, G. I. (2007) · Nature Medicine · doi:10.1038/nm1649 · Cited by 507
Translocations involving c-myc and c-myc function
Boxer, L. M., & Dang, C. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204595 · Cited by 479
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Boutros, P. C., Fraser, M., Harding, N. J., de Borja, R., Trudel, D., Lalonde, E., Meng, A., Hennings-Yeomans, P. H., McPherson, A., Sabelnykova, V. Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3315 · Cited by 477
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 465
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., M Koh, C., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 441
Boon, K., Caron, H. N., van Asperen, R., Valentijn, L., Hermus, M.-C., van Sluis, P., Roobeek, I., Weis, I., Voûte, P. A., Schwab, M., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1383 · Cited by 438
Metabolic pathways in T cell fate and function
Gerriets, V. A., & Rathmell, J. C. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.010 · Cited by 436
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., et al. (2012) · Science · doi:10.1126/science.1212728 · Cited by 433
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
Self-citationTransient excess of MYC activity can elicit genomic instability and tumorigenesis
Felsher, D. W., & Bishop, J. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3940 · Cited by 419
Self-citationAn Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
Regulation of cancer cell metabolism: Oncogenic MYC in the driver’s seat
Dong, Y., Tu, R., Liu, H., & Qing, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00235-2 · Cited by 405
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701953104 · Cited by 403
Self-citationTaking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development
Grewal, S. S., Li, L., Orian, A., Eisenman, R. N., & Edgar, B. A. (2005) · Nature Cell Biology · doi:10.1038/ncb1223 · Cited by 387
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
The role of c-myc in cellular growth control
Schmidt, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202751 · Cited by 380
Kim, J.-W., Zeller, K. I., Wang, Y., Jegga, A. G., Aronow, B. J., O'Donnell, K. A., & Dang, C. V. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5923-5936.2004 · Cited by 371
Microinjected c- myc as a Competence Factor
Kaczmarek, L., Hyland, J. K., Watt, R., Rosenberg, M., & Baserga, R. (1985) · Science · doi:10.1126/science.4001943 · Cited by 355
The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability
King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Aranda-Orgilles, B., Perez-Garcia, A., Shi, J., Vakoc, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.041 · Cited by 347
Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., & Chodosh, L. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00212-x · Cited by 345
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Self-citationTarget gene-independent functions of MYC oncoproteins
Baluapuri, A., Wolf, E., & Eilers, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0215-2 · Cited by 310
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma
Bernards, R., Dessain, S. K., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90509-x · Cited by 301
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
Reduced Expression of MYC Increases Longevity and Enhances Healthspan
Hofmann, J. W., Zhao, X., De Cecco, M., Peterson, A. L., Pagliaroli, L., Manivannan, J., Hubbard, G. B., Ikeno, Y., Zhang, Y., Feng, B., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.016 · Cited by 293
The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0650-z · Cited by 289
Pourdehnad, M., Truitt, M. L., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., & Ruggero, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310230110 · Cited by 286
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
Gustafson, W. C., Meyerowitz, J. G., Nekritz, E. A., Chen, J., Benes, C., Charron, E., Simonds, E. F., Seeger, R., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 278
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
Pei, Y., Liu, K.-W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. T., Murad, N., Morrissy, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.011 · Cited by 276
Metabolic maintenance of cell asymmetry following division in activated T lymphocytes
Verbist, K. C., Guy, C. S., Milasta, S., Liedmann, S., Kamiński, M. M., Wang, R., & Green, D. R. (2016) · Nature · doi:10.1038/nature17442 · Cited by 275
K-ras activation generates an inflammatory response in lung tumors
Ji, H., Houghton, A. M., Mariani, T. J., Perera, S., Kim, C. B., Padera, R., Tonon, G., McNamara, K., Marconcini, L. A., Hezel, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209237 · Cited by 271
Dews, M., Fox, J. L., Hultine, S., Sundaram, P., Wang, W., Liu, Y. Y., Furth, E., Enders, G. H., El-Deiry, W., Schelter, J. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2412 · Cited by 268
The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target
Zhou, X. Z., & Lu, K. P. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.49 · Cited by 266
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 259
Self-citationOncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation
Bott, A. J., Peng, I.-C., Fan, Y., Faubert, B., Zhao, L., Li, J., Neidler, S., Sun, Y., Jaber, N., Krokowski, D., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.025 · Cited by 258
Shroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., Bellovin, D. I., Tran, P. T., Philbrick, W. M., Garcia-Ocana, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507228112 · Cited by 255
Self-citationMYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
c-myc down-regulates class I HLA expression in human melanomas.
Versteeg, R., Noordermeer, I. A., Krüse-Wolters, M., Ruiter, D. J., & Schrier, P. I. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02909.x · Cited by 252
Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 250
c-myc Is a Downstream Target of the Smad Pathway
Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., Miyazono, K., & Kato, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104170200 · Cited by 244
The Expanding World of N-MYC–Driven Tumors
Rickman, D. S., Schulte, J. H., & Eilers, M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0273 · Cited by 241
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
Briggs, K. J., Koivunen, P., Cao, S., Backus, K. M., Olenchock, B. A., Patel, H., Zhang, Q., Signoretti, S., Gerfen, G. J., Richardson, A. L., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.042 · Cited by 235
Pelengaris, S., & Khan, M. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00294-7 · Cited by 225
Therapeutic Strategies to Inhibit MYC
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 222
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Brown-Swigart, L., & Evan, G. I. (2006) · Genes & Development · doi:10.1101/gad.1455706 · Cited by 200
Gouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., Tong, L., Mosley, A., Hsieh, A. L., Sullivan, D. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.012 · Cited by 200
Self-citationTargeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Kouidhi, S., Ben Ayed, F., & Benammar Elgaaied, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00353 · Cited by 196
Regulation of cell cycle duration by c-myc levels.
Karn, J., Watson, J. V., Lowe, A. D., Green, S. M., & Vedeckis, W. V. (1989) · PubMed · Cited by 192
N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
Berger, A., Brady, N. J., Bareja, R., Robinson, B., Conteduca, V., Augello, M. A., Puca, L., Ahmed, A., Dardenne, E., Lu, X., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127961 · Cited by 188
Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J. R., Tabor, V., Aichele, P., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.043 · Cited by 184
Atsaves, V, Tsesmetzis, N., Chioureas, D., Kis, L., Leventaki, V, Drakos, E., Panaretakis, T., Grander, D., Medeiros, L. J., Young, K. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.103 · Cited by 184
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S., Anastasiou, P., Swigart, L. B., Soucek, L., Arends, M. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0435 · Cited by 182
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression
Karlsson, A. E., Deb-Basu, D., Cherry, A. M., Turner, S., Ford, J. M., & Felsher, D. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732638100 · Cited by 181
Self-citationYang, D., Liu, H., Goga, A., Kim, S., Yuneva, M., & Bishop, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008366107 · Cited by 177
MAX and MYC: A Heritable Breakup
Cascón, A., & Robledo, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3891 · Cited by 176
Xiao, D., Yue, M., Su, H., Ren, P., Jiang, J., Li, F., Hu, Y., Du, H., Liu, H., & Qing, G. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.016 · Cited by 175
Li, Y., Choi, P. S., Casey, S. C., Dill, D. L., & Felsher, D. W. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.014 · Cited by 174
Self-citationCarabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
Brown, R. V., Danford, F. L., Gokhale, V., Hurley, L. H., & Brooks, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274720 · Cited by 172
Fredlund, E., Ringnér, M., Maris, J. M., & Påhlman, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804455105 · Cited by 169
Ricciardi, S., Manfrini, N., Alfieri, R., Calamita, P., Crosti, M. C., Gallo, S., Müller, R., Pagani, M., Abrignani, S., & Biffo, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.009 · Cited by 169
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
Chen, L., Alexe, G., Dharia, N. V., Ross, L. S., Iniguez, A. B., Conway, A. S., Wang, E. J., Veschi, V., Lam, N., Qi, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90793 · Cited by 168
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 167
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Kelly, G. L., Grabow, S., Glaser, S. P., Fitzsimmons, L., Aubrey, B. J., Okamoto, T., Valente, L. J., Robati, M., Tai, L., Fairlie, W. D., et al. (2014) · Genes & Development · doi:10.1101/gad.232009.113 · Cited by 166
Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland
Wang, X., Cunningham, M., Zhang, X., Tokarz, S., Laraway, B., Troxell, M., & Sears, R. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1032 · Cited by 165
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
Giuriato, S., Ryeom, S. W., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., van Riggelen, J., Kopelman, A. M., Passegue, E. A., Tang, F. L. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608017103 · Cited by 160
Self-citationDevelopmental Context Determines Latency of MYC-Induced Tumorigenesis
Beer, S., Zetterberg, A., Ihrie, R. A., McTaggart, R., Yang, Q., Bradon, N., Arvanitis, C., Attardi, L. D., Feng, S., Ruebner, B. H., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020332 · Cited by 158
Self-citationBui, T. V., & Mendell, J. T. (2010) · Genes & Cancer · doi:10.1177/1947601910377491 · Cited by 157
Lai, I. K., Swaminathan, S., Baylot, V., Mosley, A. R., Dhanasekaran, R., Gabay, M., & Felsher, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0431-x · Cited by 156
Self-citationMission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 156
Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.09.001 · Cited by 154
Alteration of the lipid profile in lymphomas induced by MYC overexpression
Eberlin, L. S., Gabay, M., Fan, A. C., Gouw, A. M., Tibshirani, R. J., Felsher, D. W., & Zare, R. N. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409778111 · Cited by 154
Self-citationSun, L., Wang, Q., Chen, B., Zhao, Y., Shen, B., Wang, H., Xu, J., Zhu, M., Zhao, X., Xu, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0988-9 · Cited by 153
Bettess, M. D., Dubois, N. C., Murphy, M., Dubey, C., Roger, C., Robine, S., & Trumpp, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7868-7878.2005 · Cited by 152
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Massó-Vallés, D., & Soucek, L. (2020) · Cells · doi:10.3390/cells9040883 · Cited by 147
Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis
Cheng, J., Park, D. E., Berrios, C. J., White, E. A., Arora, R., Yoon, R., Branigan, T. B., Xiao, T., Westerling, T., Alexander Joel Federation, et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006668 · Cited by 145
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
Kaur, S., Soto‐Pantoja, D. R., Stein, E. V., Liu, C., ELKAHLOUN, A. G., Pendrak, M. L., Nicolae, A., SINGH, S. P., Nie, Z., Levens, D., et al. (2013) · Scientific Reports · doi:10.1038/srep01673 · Cited by 143
Farrell, A. S., Pelz, C., Wang, X., Daniel, C. J., Wang, Z., Su, Y., Janghorban, M., Zhang, X., Morgan, C. W., Impey, S., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01455-12 · Cited by 143
Farrell, A. S., Joly, M. M., Allen-Petersen, B. L., Worth, P. J., Lanciault, C., Sauer, D., Link, J. M., Pelz, C., Heiser, L. M., Morton, J. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01967-6 · Cited by 143
c-MYC-Induced Genomic Instability
Kuzyk, R., & Mai, S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014373 · Cited by 141
Ohshima, K., Hatakeyama, K., Nagashima, T., Watanabe, Y., Kanto, K., Doi, Y., Ide, T., Shimoda, Y., TANABE, T., Ohnami, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00219-3 · Cited by 140
Regulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression
Reavie, L. B., Buckley, S. M., Loizou, E., Takeishi, S., Aranda-Orgillés, B., Ndiaye‐Lobry, D., Abdel-Wahab, O. I., Ibrahim, S., Nakayama, K. I., & Aifantis, I. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.025 · Cited by 133
Williamson, D., Lu, Y., Gordon, T., Sciot, R., Kelsey, A. M., Fisher, C., Poremba, C., Anderson, J. D., Pritchard‐Jones, K., & SHIPLEY, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.078 · Cited by 132
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
Self-citationFelsenstein, K. M., Saunders, L. B., Simmons, J. K., Leon, E. C., Calabrese, D. R., Zhang, S., Michalowski, A. M., Gareiss, P. C., Mock, B. A., & Schneekloth, J. S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00577 · Cited by 129
A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
Jung, M., Russell, A. J., Liu, B., George, J., Liu, P. Y., Liu, T., DeFazio, A., Bowtell, D. D. L., Oberthuer, A., London, W. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2906 · Cited by 129
Wiegering, A., Uthe, F. W., Jamieson, T. J., Ruoss, Y., Hüttenrauch, M., Küspert, M., Pfann, C., Nixon, C., Herold, S., Walz, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1040 · Cited by 127
van Riggelen, J., Müller, J., Otto, T., Beuger, V., Yetil, A., Choi, P. S., Kosan, C., Möröy, T., Felsher, D. W., & Eilers, M. (2010) · Genes & Development · doi:10.1101/gad.585710 · Cited by 127
Self-citationRoles for MYC in the Establishment and Maintenance of PluripotencyPreprint
Chappell, J., & Dalton, S. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014381 · Cited by 123
Zhao, X. L., Lwin, T., Zhang, X., Huang, A., Wang, J., Márquez, V. E., Chen‐Kiang, S., Dalton, W. S., Sotomayor, E., & Tao, J. (2013) · Leukemia · doi:10.1038/leu.2013.94 · Cited by 121
Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis
Diolaiti, D., McFerrin, L. G., Carroll, P. A., & Eisenman, R. N. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.016 · Cited by 121
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation
Sharma, S. V., Fischbach, M. A., Haber, D. A., & Settleman, J. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0096 · Cited by 117
Chromosomal regions involved in the pathogenesis of osteosarcomas
Stock, C., Kager, L., Fink, F., Gadner, H., & Ambros, P. F. (2000) · Genes Chromosomes and Cancer · doi:10.1002/1098-2264(200007)28:3<329::aid-gcc11>3.0.co;2-f · Cited by 117
Li, W., Gupta, S. K., Han, W., Kundson, R. A., Nelson, S., Knutson, D. L., Greipp, P. T., Elsawa, S. F., Sotomayor, E. M., & Gupta, M. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0761-2 · Cited by 116
MYC Can Induce DNA Breaks In vivo and In vitro Independent of Reactive Oxygen Species
Ray, S., Atkuri, K. R., Deb-Basu, D., Adler, A. S., Chang, H. Y., Herzenberg, L. A., & Felsher, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3115 · Cited by 114
Self-citationMYC: Master Regulator of Immune Privilege
Casey, S. C., Baylot, V., & Felsher, D. W. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.002 · Cited by 114
Self-citationMelaiu, O., Mina, M., Chierici, M., Boldrini, R., Jurman, G., Romania, P., D’Alicandro, V., Benedetti, M. C., Castellano, A., Liu, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2601 · Cited by 113
Devi, G. R., Beer, T. M., Corless, C. L., Arora, V., Weller, D. L., & Iversen, P. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2091 · Cited by 111
Allison, K. E., Coomber, B. L., & Bridle, B. W. (2017) · Immunology · doi:10.1111/imm.12777 · Cited by 109
Kretzner, L., Scuto, A., Dino, P. M., Kowolik, C. M., Wu, J., Ventura, P. B., Jove, R., Forman, S. J., Yen, Y., & Kirschbaum, M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2259 · Cited by 107
Röschert, I., Poon, E., Henssen, A. G., García, H. D., Gatti, M., Giansanti, C., Jamin, Y., Ade, C. P., Gallant, P., Schülein‐Völk, C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00171-8 · Cited by 105
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Koh, C. M., Sabò, A., & Guccione, E. (2016) · BioEssays · doi:10.1002/bies.201500134 · Cited by 102
Hu, M.-H., Wang, Y.-Q., Yu, Z.-Y., Hu, L.-N., Ou, T.-M., Chen, S.-B., Huang, Z.-S., & Tan, J.-H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01697 · Cited by 101
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer
Kharma, B., Baba, T., Matsumura, N., Kang, H., Hamanishi, J., Murakami, R., McConechy, M. M., Leung, S. C. Y., Yamaguchi, K. D., Hosoe, Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0847 · Cited by 97
Dutta, D., Debnath, M., Müller, D., Paul, R., Das, T., Bessi, I., Schwalbe, H., & Dash, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky385 · Cited by 96
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma
Bailey, S. T., Smith, A. M., Kardos, J., Wobker, S. E., Wilson, H. L., Krishnan, B., Saito, R., Lee, H. J., Zhang, J., Eaton, S. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms15770 · Cited by 95
Self-citationGenomic and Proteomic Analysis Reveals a Threshold Level of MYC Required for Tumor Maintenance
Shachaf, C. M., Gentles, A. J., Elchuri, S. V., Sahoo, D., Soen, Y., Sharpe, O., Perez, O. D., Chang, M., Mitchel, D., Robinson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6192 · Cited by 93
Self-citationLevens, D. (2010) · Genes & Cancer · doi:10.1177/1947601910377492 · Cited by 93
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
Demma, M. J., Mapelli, C., Sun, A., Bodea, S., Ruprecht, B., Javaid, S., Wiswell, D., Muise, E., Chen, S., Zelina, J., et al. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-19 · Cited by 92
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K. M., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002125 · Cited by 90
Self-citationDammert, M. A., Brägelmann, J., Olsen, R. R., Böhm, S., Monhasery, N., Whitney, C. P., Chalishazar, M. D., Tumbrink, H. L., Guthrie, M. R., Klein, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11371-x · Cited by 90
The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo
Reimann, M., Loddenkemper, C., Rudolph, C., Schildhauer, I., Teichmann, B., Stein, H., Schlegelberger, B., Dörken, B., & Schmitt, C. A. (2007) · Blood · doi:10.1182/blood-2007-02-075614 · Cited by 88
Pai, S., Bamodu, O. A., Lin, Y., Lin, C., Chu, P., Chien, M., Wang, L.-S., Hsiao, M., Yeh, C., & Tsai, J.-T. (2019) · Cells · doi:10.3390/cells8121658 · Cited by 88
Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis
Cao, J., Ge, M., & Ling, Z. (2016) · Medicine · doi:10.1097/md.0000000000002496 · Cited by 83
Panda, D., Saha, P., Das, T., & Dash, J. (2017) · Nature Communications · doi:10.1038/ncomms16103 · Cited by 81
Swaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Liefwalker, D. F., Horton, C. E., Mosley, A. R., Liebersbach, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16447-7 · Cited by 80
Self-citationThrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47
Kamijo, H., Miyagaki, T., Shishido-Takahashi, N., Nakajima, R., Oka, T., Suga, H., Sugaya, M., & Sato, S. (2019) · Leukemia · doi:10.1038/s41375-019-0622-6 · Cited by 75
Dhanasekaran, R., Baylot, V., Kim, M., Kuruvilla, S. P., Bellovin, D. I., Adeniji, N., Rajan, A., Lai, I. K., Gabay, M., Tong, L., et al. (2020) · eLife · doi:10.7554/elife.50731 · Cited by 73
Self-citationCould MYC Induction of Mitochondrial Biogenesis be linked to ROS Production and Genomic Instability?
Dang, C. V., Li, F., & Lee, L. A. (2005) · Cell Cycle · doi:10.4161/cc.4.11.2121 · Cited by 69
PIN1 in Cell Cycle Control and Cancer
Cheng, C.-W., & Tse, E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01367 · Cited by 69
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Pan, Y., Fei, Q., Xiong, P., Yang, J., Zhang, Z., Lin, X., Pan, M., Lu, F., & Huang, H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581529 · Cited by 68
Targeting MYC Proteins for Tumor Therapy
Wolf, E., & Eilers, M. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055826 · Cited by 68
c-Myc Suppression of DNA Double-strand Break Repair
Li, Z., Owonikoko, T. K., Sun, S., Ramalingam, S. S., Doetsch, P. W., Xiao, Z., Khuri, F. R., Curran, W. J., & Deng, X. (2012) · Neoplasia · doi:10.1593/neo.121258 · Cited by 67
Rosenwald, I. B. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04171-7 · Cited by 66
Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma
Zhou, L., Picard, D. J., Ra, Y., Li, M., Northcott, P. A., Hu, Y., Stearns, D. S., Hawkins, C. E., Taylor, M. D., Rutka, J. T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4562 · Cited by 60
Williams, R. D., Al‐Saadi, R., Natrajan, R., Mackay, A. G., Chagtai, T., Little, S. E., Hing, S., Fenwick, K., Ashworth, A., Grundy, P. E., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20907 · Cited by 59
El‐Jawhari, J. J., El-Sherbiny, Y. M., Scott, G. B., Morgan, R. S. M., Prestwich, R. J. D., Bowles, P. A., Blair, G. E., Tanaka, T. U., Rabbitts, T. H., Meade, J. L., et al. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.020 · Cited by 58
c-myc antisense oligonucleotide treatment ameliorates murine ARPKD
Ricker, J. L., Mata, J. E., Iversen, P. L., & Gattone, V. H. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.0610s1125.x · Cited by 57
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age
Thng, D. K. H., Toh, T. B., & Chow, E. K. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.014 · Cited by 57
Control of Cell Proliferation and Growth by Myc Proteins
Bernard, S., & Eilers, M. (2006) · Springer eBooks · doi:10.1007/400_004 · Cited by 56
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies
Adams, C. M., Hiebert, S. W., & Eischen, C. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1751 · Cited by 53
Lernoux, M., Schnekenburger, M., Losson, H., Vermeulen, K., Hahn, H., Gérard, D., Lee, J., Mazumder, A., Ahamed, M., Christov, C., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00839-z · Cited by 49
What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas
Dudley, J., Mertz, J., Rajan, L., Lozano, M. M., & Broussard, D. R. (2002) · Leukemia · doi:10.1038/sj.leu.2402451 · Cited by 46
Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation
Tran, P. T., Bendapudi, P. K., Lin, H. J., Choi, P. S., Koh, S., Chen, J., Horng, G., Hughes, N. P., Schwartz, L. H., Miller, V. A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002018 · Cited by 45
Self-citationAnti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)
Dhanasekaran, R., Gabay, M., Baylot, V., Lai, I. K., Mosley, A. R., Huang, X., Zabludoff, S., Li, J., Kaimal, V., Karmali, P. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22342 · Cited by 45
Self-citation
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Metadata
- Authors
- Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-09-10
- Volume
- 19
- Issue
- 1
- Pages
- 23-36
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3196329163
- Cited by
- 986
- References
- 223
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.